Shopping Cart 0
Cart Subtotal
USD 0

Midatech Pharma US Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Midatech Pharma US Inc (Midatech Pharma), formerly DARA BioSciences, Inc., is a pharmaceutical company which focuses on the development and commercialization of cancer treatment and supportive care products. It is a subsidiary of Midatech Pharma Plc. The company's product portfolio includes Gelclair, a treatment for oral mucositis; Zuplenz, a treatment for the prevention of nausea and vomiting in adult patients and Oravig, for the treatment of oral thrush. The company collaborates with pharmaceutical companies such as Mission Pharmacal to commercialize its product cancer supportive care products. It distributes its products through retail pharmacies, mail order pharmacies, and long-term care facilities in the US. Midatech Pharma is headquartered in Raleigh, North Carolina, the US.

Midatech Pharma US Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Midatech Pharma US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Midatech Pharma US Inc, Medical Devices Deals, 2012 to YTD 2018 9

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

Kanwa Holdings Acquires Midatech Pharma US from Midatech Pharma 11

Partnerships 13

Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 13

Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 14

DARA BioSciences Enters into Commercialization Agreement with Onxeo 15

DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 16

Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 17

Licensing Agreements 18

Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 18

DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 19

DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 20

Equity Offering 21

Dara BioSciences Raises USD12.5 Million in Public Offering of Units 21

Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To USD 32.5 Million 23

Dara BioSciences Raises USD6 Million in Private Placement Of Shares 24

Dara BioSciences Completes Private Placement Of Shares For USD 2.6 Million 25

Dara BioSciences Announces Public Offering Of Common Stock For USD 2.7 Million 26

Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For USD 2.6 Million 27

Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For USD 0.3 Million 28

DARA BioSciences Completes Public Offering Of Units For USD 10 Million 29

DARA BioSciences Completes Private Placement Of Preferred Stock For USD 1.7 Million 31

Acquisition 33

Midatech Pharma Acquires Dara BioSciences 33

DARA BioSciences Acquires Oncogenerix 35

Midatech Pharma US Inc-Key Competitors 36

Midatech Pharma US Inc-Key Employees 37

Midatech Pharma US Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Sep 27, 2018: Midatech Pharma: Interim results for the six months ended 30 June 2018 39

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Midatech Pharma US Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Key Facts 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Midatech Pharma US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Midatech Pharma US Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Midatech Pharma US Inc, Medical Devices Deals, 2012 to YTD 2018 9

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kanwa Holdings Acquires Midatech Pharma US from Midatech Pharma 11

Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 13

Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 14

DARA BioSciences Enters into Commercialization Agreement with Onxeo 15

DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 16

Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 17

Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 18

DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 19

DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 20

Dara BioSciences Raises USD12.5 Million in Public Offering of Units 21

Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To USD 32.5 Million 23

Dara BioSciences Raises USD6 Million in Private Placement Of Shares 24

Dara BioSciences Completes Private Placement Of Shares For USD 2.6 Million 25

Dara BioSciences Announces Public Offering Of Common Stock For USD 2.7 Million 26

Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For USD 2.6 Million 27

Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For USD 0.3 Million 28

DARA BioSciences Completes Public Offering Of Units For USD 10 Million 29

DARA BioSciences Completes Private Placement Of Preferred Stock For USD 1.7 Million 31

Midatech Pharma Acquires Dara BioSciences 33

DARA BioSciences Acquires Oncogenerix 35

Midatech Pharma US Inc, Key Competitors 36

Midatech Pharma US Inc, Key Employees 37

Midatech Pharma US Inc, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Midatech Pharma US Inc (Midatech Pharma), formerly DARA BioSciences, Inc., is a pharmaceutical company which focuses on the development and commercialization of cancer treatment and supportive care products. It is a subsidiary of Midatech Pharma Plc. The company's product portfolio includes Gelclair, a treatment for oral mucositis; Zuplenz, a treatment for the prevention of nausea and vomiting in adult patients and Oravig, for the treatment of oral thrush. The company collaborates with pharmaceutical companies such as Mission Pharmacal to commercialize its product cancer supportive care products. It distributes its products through retail pharmacies, mail order pharmacies, and long-term care facilities in the US. Midatech Pharma is headquartered in Raleigh, North Carolina, the US.

Midatech Pharma US Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Midatech Pharma US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Midatech Pharma US Inc, Medical Devices Deals, 2012 to YTD 2018 9

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

Kanwa Holdings Acquires Midatech Pharma US from Midatech Pharma 11

Partnerships 13

Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 13

Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 14

DARA BioSciences Enters into Commercialization Agreement with Onxeo 15

DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 16

Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 17

Licensing Agreements 18

Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 18

DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 19

DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 20

Equity Offering 21

Dara BioSciences Raises USD12.5 Million in Public Offering of Units 21

Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To USD 32.5 Million 23

Dara BioSciences Raises USD6 Million in Private Placement Of Shares 24

Dara BioSciences Completes Private Placement Of Shares For USD 2.6 Million 25

Dara BioSciences Announces Public Offering Of Common Stock For USD 2.7 Million 26

Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For USD 2.6 Million 27

Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For USD 0.3 Million 28

DARA BioSciences Completes Public Offering Of Units For USD 10 Million 29

DARA BioSciences Completes Private Placement Of Preferred Stock For USD 1.7 Million 31

Acquisition 33

Midatech Pharma Acquires Dara BioSciences 33

DARA BioSciences Acquires Oncogenerix 35

Midatech Pharma US Inc-Key Competitors 36

Midatech Pharma US Inc-Key Employees 37

Midatech Pharma US Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Sep 27, 2018: Midatech Pharma: Interim results for the six months ended 30 June 2018 39

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Midatech Pharma US Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Key Facts 2

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Midatech Pharma US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Midatech Pharma US Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Midatech Pharma US Inc, Medical Devices Deals, 2012 to YTD 2018 9

Midatech Pharma US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kanwa Holdings Acquires Midatech Pharma US from Midatech Pharma 11

Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 13

Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 14

DARA BioSciences Enters into Commercialization Agreement with Onxeo 15

DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 16

Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 17

Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 18

DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 19

DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 20

Dara BioSciences Raises USD12.5 Million in Public Offering of Units 21

Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To USD 32.5 Million 23

Dara BioSciences Raises USD6 Million in Private Placement Of Shares 24

Dara BioSciences Completes Private Placement Of Shares For USD 2.6 Million 25

Dara BioSciences Announces Public Offering Of Common Stock For USD 2.7 Million 26

Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For USD 2.6 Million 27

Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For USD 0.3 Million 28

DARA BioSciences Completes Public Offering Of Units For USD 10 Million 29

DARA BioSciences Completes Private Placement Of Preferred Stock For USD 1.7 Million 31

Midatech Pharma Acquires Dara BioSciences 33

DARA BioSciences Acquires Oncogenerix 35

Midatech Pharma US Inc, Key Competitors 36

Midatech Pharma US Inc, Key Employees 37

Midatech Pharma US Inc, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS